We are pleased to announce that Rhéon Medical, one of our Life Sciences pillar investments was granted Breakthrough Device Designation by the US Food and Drug Administration (FDA) on May 21 in Lausanne. Such grants are provided to medical devices that have the potential to provide a more effective treatment for life-threatening or irreversibly debilitating diseases, with a view to speed up development whilst preserving statutory standards.
Based on a unique proprietary patented technology, the eyeWatch device is designed to offer non-invasive, patient-specific flow and pressure control, providing the means to avoid hypotony-related complications. The eyeWatch technology has already received the CE-mark in 2019 and is currently marketed in European and Asian markets, with expected initiation of US-based clinical trials evaluating the therapy in early 2022. For more details see their website here.
